THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Kathleen Moore to Maximum Tolerated Dose

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Maximum Tolerated Dose.
Kathleen Moore
Connection Strength
0.320
Maximum Tolerated Dose
  1. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 08; 154(2):294-301.
    View in: PubMed
    Score: 0.164
  2. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
    View in: PubMed
    Score: 0.155
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES